MediQuest Concludes Confirmatory Phase III Study of Raynaud's Therapy

(BOTHELL, WA - June 25) - MediQuest Therapeutics, Inc., a specialty pharmaceutical company focused on developing therapies for inflammatory and infectious diseases, today announced the completion of its confirmatory phase III study of MQX-503 - a topical formulation designed to treat Raynaud's Disease.

The study met its primary end point and demonstrated statistical significance, with p = 0.008 for the Intent-to-Treat patient population. Typically, a probability value (p) less than .05 is commonly accepted as establishing statistical significance between treatment groups.

"With the conclusion of this clinical study, MediQuest is one step closer to submitting the MQX-503 New Drug Application to the FDA," said MediQuest President and CEO Dr. Frederick Dechow. "If approved, Vascana would be the first drug on the market specifically designed to prevent and treat Raynaud's symptoms, providing clinicians with a needed treatment for patients."

MQX-503 has the potential of satisfying an unmet medical need for more than 2 million Americans seeking care for Raynaud's Disease.

In addition to MQX-503, MediQuest's ongoing developmental efforts have generated a robust pipeline that includes three drug candidates in clinical trials, one at the pre-clinical stage and others at the research stage. The company develops first- and best-in-class topical therapies to treat patients suffering from inflammatory and infectious diseases.